Dr. Michael Williams on Lenalidomide Plus Rituximab in First- Line MCL

Michael E. Williams, MD, ScM
Published: Saturday, Mar 19, 2016



Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses a phase II study that explored frontline lenalidomide (Revlimid) and rituximab (Rituxan) for patients with mantle cell lymphoma (MCL). 

In this multicenter, phase II study, led by Jia Ruan, MD, at Weill Cornell Medicine, patients with MCL were treated with lenalidomide and rituximab in both the induction and maintenance setting. At 30 months, the overall response rate for evaluable patients was 92%, and the complete response rate was 64% (95% CI, 46 - 79).

Although it was a small study that only included 38 patients, these findings were impressive, says Williams. The study shows that nonchemotherapy-based approaches can still be very effective, he says. Interestingly, patients experienced the same benifits with the lenalidomide and rituximab combination regardless of whether or not they were classified as having lower or higher-risk MCL, WIlliams notes.

<<< View more from the 2016 Congress on Hematologic Malignancies



Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses a phase II study that explored frontline lenalidomide (Revlimid) and rituximab (Rituxan) for patients with mantle cell lymphoma (MCL). 

In this multicenter, phase II study, led by Jia Ruan, MD, at Weill Cornell Medicine, patients with MCL were treated with lenalidomide and rituximab in both the induction and maintenance setting. At 30 months, the overall response rate for evaluable patients was 92%, and the complete response rate was 64% (95% CI, 46 - 79).

Although it was a small study that only included 38 patients, these findings were impressive, says Williams. The study shows that nonchemotherapy-based approaches can still be very effective, he says. Interestingly, patients experienced the same benifits with the lenalidomide and rituximab combination regardless of whether or not they were classified as having lower or higher-risk MCL, WIlliams notes.

<<< View more from the 2016 Congress on Hematologic Malignancies




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x